¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Vaccination, pneumococcal pneumonia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hypostatic pneumonia
    ħ°­¼ºÆó·Å
  • indurative pneumonia
    °æÈ­Æó·Å
  • inhalation pneumonia
    ÈíÀÔÆó·Å
  • interstitial plasma cell pneumonia
    »çÀÌÁúÇüÁú¼¼Æ÷Æó·Å, ÆóÆ÷ÀÚÃæÁõ
  • interstitial pneumonia
    °£ÁúÆó·Å, »çÀÌÁúÆó·Å
  • lipid pneumonia
    ÁöÁúÆó·Å
  • lobar pneumonia
    ¿±(¼º)Æó·Å
  • lobular pneumonia
    ¼Ò¿±Æó·Å, ±â°üÁöÆó·Å
  • lymphoid interstitial pneumonia
    ¸²ÇÁ±¸»çÀÌÁúÆó·Å, ¸²ÇÁ±¸°£ÁúÆó·Å
  • migratory pneumonia
    À̵¿Æó·Å, ÀÌÁÖÆó·Å
  • nosocomial pneumonia
    º´¿ø³»Æó·Å
  • pneumonia
    Æó·Å, ÇãÆÄ¿°
  • primary atypical pneumonia
    ¿ø¹ßºñÁ¤ÇüÆó·Å
  • rheumatic pneumonia
    ·ù¸¶Æ¼½ºÆó·Å
  • staphylococcal pneumonia
    Æ÷µµ¾Ë±ÕÆó·Å, Æ÷µµ±¸±ÕÆó·Å
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhalation pneumonia
    ÈíÀÔÆó·Å
  • interstitial pneumonia
    °£ÁúÆó·Å, »çÀÌÁúÆó·Å
  • lipid pneumonia
    ÁöÁúÆó·Å
  • lobar pneumonia
    ¿±Æó·Å
  • lobular pneumonia
    (¢¡bronchopneumonia) ±â°üÁöÆó·Å
  • migratory pneumonia
    À¯ÁÖÆó·Å
  • pneumonia
    Æó·Å, ÇãÆÄ¿°
  • rheumatic pneumonia
    ·ù¸¶Æ¼½ºÆó·Å
  • secondary pneumonia
    ¼Ó¹ßÆó·Å
  • septic pneumonia
    ÆÐÇ÷Æó·Å
  • staphylococcal pneumonia
    Æ÷µµ¾Ë±ÕÆó·Å
  • streptococcal pneumonia
    »ç½½¾Ë±ÕÆó·Å
  • typhoid pneumonia
    ÀåÆ¼Çª½ºÆó·Å
  • viral pneumonia
    ¹ÙÀÌ·¯½ºÆó·Å
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pneumococcal meningitis
    Æó·Å±¸±Õ(¼º) ¼ö¸·¿°(øËæúϹжàõâÐØ¯æú).
  • pneumococcal septicemia
    Æó·Å±¸±Õ(¼º) ÆÐÇ÷Áõ(øËæúϹжàõø¨úìñø).
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • Eatons agent pneumonia
    ÀÌÆ°º´¿øÃ¼Æó·Å.
  • Loeffler s pneumonia
    ·ÚÇ÷¯Æó·Å.
  • Pittsburgh pneumonia [agent]
    ÇÇÃ÷¹ö±×Æó·Å(¿øÀÎü), ·¹Áö¿À³Ú¶óÁõ(¿øÀÎü)
  • Pneumocystis carinii pneumonia
    ÁÖÆóÆ÷ÀÚÃþ Æó·Å.
  • acute pneumonia
    ±Þ¼ºÆó·Å (~øËæú)
  • acute pneumonia
    ±Þ¼º Æó·Å(¡­øËæú).
  • acute pneumonia
    ±Þ¼º Æó·Å(?̰Ëç).
  • acute tuberculous pneumonia
    ±Þ¼º °áÇÙ¼º Æó·Å(¡­Ì¿ú·àõøËæú).
  • ambulatory pneumonia
    À¯ÁÖ¼º Æó·Å(ë´ñËàõøËæú).
  • apical pneumonia
    Æó÷ºÎÆó·Å(¡­øËæú).
  • ascariasis pneumonia
    È¸Ãæ¼º Æó·Å.
  • giant cell pneumonia
    °Å¼¼Æ÷Æó·Å.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pneumococcal endocarditis
    Æó·Å±¸±Õ(¼º) ½É³»¸·¿°(øËæúϹжàõãýҮدæú).
  • pneumococcal infection
    Æó·Å±¸±Õ°¨¿°(øËæúϹжÊïæø).
  • pneumococcal infection
    Æó·Å±¸±Õ°¨¿°(øËæúϹжÊïæø)
  • pneumococcal memingitis
    Æó·Å±¸±Õ¼º ¼ö¸·¿°(³ú¸·¿°)(øËæúϹжàõ â©Ø¯æú(ÒàØ¯æú))
  • pneumococcal meningitis
    Æó·Å±¸±Õ(¼º) ¼ö¸·¿°(øËæúϹжàõâÐØ¯æú).
  • pneumococcal septicemia
    Æó·Å±¸±Õ(¼º) ÆÐÇ÷Áõ(øËæúϹжàõø¨úìñø).
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • regional vaccination.
    °¨¿°¹®¹é½ÅÁÖ»ç(ÊïæøÚ¦¡­ñ¼ÞÒ).
  • smallpox vaccination
    µÎâ (Ôãóê) ¿¹¹æÁ¢Á¾
  • smallpox vaccination
    Á¾µÎ(ðúÔã).
  • smallpox vaccination
    Á¾µÎ(ðúÔã).
  • subcutaneous vaccination
    ÇÇÇÏÁ¾µÎ¹ý (¡­ðúÔãÛö).
  • typhoid vaccination
    ÀåÆ¼Çª½º¿¹¹æÁ¢Á¾(ÊÙËçËÑËøÌ¡).
  • typhoid vaccination
    ÀåÆ¼Çª½º¿¹¹æÁ¢Á¾(¡­çãÛÁïÈðú).
  • vaccination
    ¿¹¹æÁ¢Á¾
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • rheumatic pneumonia
    ·ù¸¶Æ¼½º¼ºÆó·Å
  • round pneumonia
    ¿øÇüÆó·Å
  • secondary pneumonia
    ¼Ó¹ß¼ºÆó·Å
  • septic pneumonia
    ÆÐÇ÷¼ºÆó·Å
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PPS Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc...
BIP Brochiolar Interstitial Pneumonia
DIP   1) Drip Infusion Pyelography
  2) Desquamative Interstitial Pneumonia
&n...
GIP   1) Giant cell Interstitial Pneumonia
  2) Gastric Inhibitory (Poly)Peptide
LIP Lymphoid Interstitial Pneumonia
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PCP pneumococcal capsular polysaccharide
AEP Acute eosinophilic pneumonia
BOOP Bronchiolitis Obliterans Organising Pneumonia
BOOP Bronchiolitis obliterans with organizing pneumonia
CEP Chronic eosinophilic pneumonia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • interstitial pneumonia
    °£Áú¼º Æó·Å
  • migratory pneumonia
    À¯ÁÖ Æó·Å
  • mycotic pneumonia
    Áø±Õ¼º Æó·Å.
  • plasma cell pneumonia
    ÇüÁú ¼¼Æ÷¼º Æó·Å
  • pneumonia
    Æó·Å
    1. ÆóÀÇ ¿°Áõ. ÇÕº´ÁõÀ» °¡Áø ÆóÀÇ ¿°Áõ. 2. Æó¿¡ »ý±â´Â ¿°Áõ. º´¸®ÇغÎÇÐÀûÀ¸·Î ÆóÀÇ ´ë¿± ÀüºÎ¿¡ ¿°ÁõÀÌ ÆÛÁø ´ë¿±¼º Æó·Å°ú, ¼Ò¿± ´ÜÀ§¿¡ ÇÑÁ¤µÈ ¼Ò¿±¼ºÆó·ÅÀ¸·Î ³ª´µ¸ç, º´¿øÃ¼¿¡ µû¶ó¼­µµ ¼¼±Õ¼º Æó·Å°ú ¹ÙÀÌ·¯½º¼º Æó·Å, ¾Ë·¹¸£±â¼º Æó·Å µîÀ¸·Î ³ª´¶´Ù. ¡¼´ë¿±¼º Æó·Å¡½ Å©·çÇÁ¼º Æó·ÅÀ̶ó°íµµ Çϸç, ¿øÀÎÀº ´ëºÎºÐÀÌ Æó·Å ±¸±ÕÀÌ´Ù. ¶§·Î´Â Æó·Å °£±Õ, Æ÷µµ»ó ±¸±Õ, ¿¬¼â ±¸±Õ¿¡ ÀÇÇÏ´Â °Íµµ ÀÖ´Ù. Áõ¼¼´Â ¿ÀÇÑ, ÀüÀ²À» ¼ö¹ÝÇÑ ¹ß¿­ ¿Ü¿¡ ±âħ, ÈäÅë, ³ì»ö °¡·¡, È£Èí °ï¶õ, Ä¡¾Æ³ëÁ¦ µîÀ̸ç, ûÁøÇϸé È¯ÃøÀÇ Æó¾ß´Â È£ÈíÀ½ÀÌ ¾àÇϰí ÀÛÀº ¼öÆ÷À½, ±â°üÁöÀ½ µîÀÌ µé¸°´Ù. X¼± »çÁøÀ¸·Î´Â ÀÌȯµÈ Æó¿±¿¡ ÀÏÄ¡µÈ °æ°è°¡ ¶Ñ·ÇÇÑ À½¿µÀ» ÀÎÁ¤ÇÒ ¼ö ÀÖ´Ù. Ä¡·á´Â Ç×»ý ¹°Áú, ƯÈ÷ ¿øÀÎ ±Õ¿¡ ´ëÇØ °¡Àå À¯È¿ÇÑ °ÍÀ» »ç¿ëÇÑ´Ù. È£Èí °ï¶õÀÌ ½ÉÇÏ¸é »ê¼Ò ÈíÀÔ, ½ÉÀåÀÌ ¼è¾àÇÏ¸é °­½ÉÁ¦¸¦ »ç¿ëÇÏ°í ´ëÁßÀûÀ¸·Î ÁøÅëÁ¦, ÁøÇØÁ¦, ÇØ¿­Á¦¸¦ »ç¿ëÇÑ´Ù. ¡¼±â°üÁö Æó·Å¡½ ±â°üÁöÀÇ ¿°ÁõÀÌ ³»ºÎ±îÁö ÆÛÁ®Æó Á¶Á÷¿¡ À̸£·¯ ÀϾ´Â °ÍÀ¸·Î, ¿øÀÎ ±ÕÀº Æó·Å ±ÕÀ̳ª ±× ¹ÛÀÇ È­³ó±ÕÀÌ´Ù. Áõ¼¼´Â º´¼ÒÀÇ Å©±â³ª ¿øÀÎ ±Õ¿¡ µû¶ó ´Ù¸£Áö¸¸, ±âħ, ¹ß¿­, ¹ßÇÑ, È£Èí °ï¶õ, Ä¡¾Æ³ëÁ¦, ÈäÅë µîÀÌ ÀÖ´Ù. X¼± »çÁøÀ¸·Î´Â °æ°è°¡ ¼±¸íÇÏÁö ¸øÇÑ ºÒ±ÔÄ¢ÀûÀÎ ÀÛÀº À½¿µÀÌ »êÀçÇÑ´Ù. ûÁøÇϸé È¯Ãø¿¡ ¼öÆ÷À½ µîÀÇ ÀâÀ½ÀÌ µé¸°´Ù. Ä¡·á´Â ¾ÕÀÇ ´ë¿±¼º Æó·Å°ú °°´Ù. ¡¼¹ÙÀÌ·¯½º¼º Æó·Å¡½ ¿ø¹ß¼º ÀÌÇü Æó·Å, ÀÎÇ÷翣ÀÚ Æó·Å, ¾Þ¹«º´¹ÙÀÌ·¯½º Æó·Å, ¾Æµ¥³ë ¹ÙÀÌ·¯½º Æó·Å µîÀÌ ÀÖ´Ù. ¿ø¹ß¼º ÀÌÇü Æó·ÅÀº °æ¹ÌÇÑ ¹ß¿­°ú ½ÉÇÑ ±âħ, °¡·¡, ÈäÅëÀÌ ÁÖ¿ä Áõ¼¼ÀÌ´Ù. X¼± »çÁø¿¡¼­´Â Æó¹®ºÎ¿¡¼­ ¸»ÃÊ·Î ÇâÇÏ´Â ¿¯Àº ±ÕÀÏÇÑ À½¿µÀÌ Æ¯Â¡À̸ç ÇÏÆó¾ß¿¡¼­ º¼ ¼ö ÀÖ´Ù. Áø´Ü¿¡´Â ÀûÇ÷±¸ ÇÑ·© ÀÀÁý ¹ÝÀÀÀ̳ª ¿¬¼â ±¸±Õ MG ÀÀÁý ¹ÝÀÀÀÌ À¯È¿ÇÏ´Ù. Ä¡·á¿¡´Â Åׯ®¶ó»çÀÌŬ¸°
  • pneumonia,in immunocompromised host
    ¸é¿ª ±â´É ÀúÇÏ ¼÷ÁÖÀÇ
  • postoperative pneumonia
    ¼ö¼úÈÄ Æó·Å, ¼úÈÄ Æó·Å
  • rheumatic pneumonia
    ·ù¸¶Æ¼½º¼º Æó·Å
  • rickettsial pneumonia
    ¸®ÄÉÄ¡¾Æ¼º Æó·Å
  • round pneumonia
    ¿øÇü Æó·Å
  • secondary pneumonia
    ¼Ó¹ß¼º Æó·Å
  • septic pneumonia
    ÆÐÇ÷¼º Æó·Å
  • serous pneumonia
    Àå¾×¼º Æó·Å
  • staphylococcal pneumonia
    Æ÷µµ ±¸±Õ¼º Æó·Å
  • suppurative pneumonia
    È­³ó¼º Æó·Å
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
vaccination, dpt DPT immunization protects from diphtheria, pertussis (whooping cough), and tetanus and is given in a series of 5 shots at 2, 4, 6, 18 months of age and 4-6 years of age. Thanks to vaccination programs, these diseases have become less common. However, there are still unvaccinated individuals capable of carrying and passing diphtheria and pertussis to others who are not vaccinated. Tetanus bacteria are prevalent in natural surroundings, such as contaminated soil. See also vaccination, dtap.
(12 Dec 1998)
vaccination, dt DT (diphtheria and tetanus) vaccine does not protect from pertussis and is usually reserved for individuals who have had a significant adverse reaction to a dpt shot or who have a personal or family history of a seizure disorder or brain disease
(12 Dec 1998)
vaccination, dtap Like DPT, DTaP protects from diphtheria, pertussis (whooping cough) and tetanus. Dtap is the same as dtp, except that it contains only acellular pertussis vaccine which is thought to cause fewer of the minor reactions associated with immunization and is also probably less likely to cause the more severe reactions occasionally seen following pertussis vaccination. Dtap is currently recommended only for the shots given at 18 months and 4-6 years of age.
(12 Dec 1998)
vaccination, german measles See Vaccination, MMR.
(12 Dec 1998)
vaccination, haemophilus influenzae type b See vaccination, hib.
(12 Dec 1998)
vaccination, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
vaccination, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
vaccination, hib This vaccine is to prevent disease caused by the haemophilus influenzae type b (hib) bacteria. The h. Influenzae (h. Flu) bacteria can cause a range of serious diseases including meningitis with potential brain damage and epiglottitis with airway obstruction poisoning. The hib vaccine is usually given at 2, 4 and 6 months of age. A final booster is given at 12-15 months of age. Hib vaccine rarely causes severe reactions.
(12 Dec 1998)
vaccination, infectious hepatitis See Vaccination, hepatitis a.
(12 Dec 1998)
vaccination, measles See Vaccination, MMR. Vaccination, mmr: the standard vaccine given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination hould be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
vaccination, mumps See Vaccination, MMR. Vaccination, pneumococcal pneumonia: this vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease (copd) or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children.
(12 Dec 1998)
vaccination, polio The vaccines available for vaccination against polio are opv (oral polio vaccine) and ipv (inactivated polio vaccine). Opv is still the preferred vaccine for most children. As its name suggests, it is given by mouth. Ipv, or inactivated polio vaccine is given as a shot in the arm or leg. Infants and children should be given four doses of opv. The doses are given at 2 months, 4 months, 6-18 months and 4-6 years of age. Persons allergic to eggs or the drugs neomycin or streptomycin should receive opv, not the injectable ipv. Conversely, ipv should be given if the vaccine recipient is on long-term steroid (cortisone) therapy, has cancer, or is on chemotherapy or if a household member has aids or there is an unimmunised adult in the house.
(12 Dec 1998)
vaccination, rubella See Vaccination, MMR.
(12 Dec 1998)
vaccination, varicella zoster See Vaccineation, chickenpox.
(12 Dec 1998)
varicella vaccination See Vaccination, chickenpox.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á